Clayton has been with Freeman Technology since 2008 in a role that has encompassed both sales and applications support. As operations manager he will be responsible for all the day-to-day activities of the company, including overall management of the administration, production, r&d, sales and customer support teams.
In expanding the management team Tim Freeman, director of operations, anticipates further growth and greater opportunity to contribute expertise to the powder processing industries.
‘We want to deliver the best possible technical and applications support to our customers at all times and part of Jamie’s new role will be to ensure that every aspect of our operation runs efficiently,’ he said.
Freeman Technology appoints operations manager
Jamie Clayton takes responsibility for day-to-day activities
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology